[Ipilimumab, a new molecular targetted therapy of malignant neoplastic disease].
Ipilimumab is a fully human monoclonal antibody that binds to CTLA-4(cytotoxic T lymphocyte-associated antigen 4). It is intended to be used as a drug to activate the immune system by binding to CTLA-4, which suppresses T-cells in natural immune responses. Recently, a phase III , multi-center, randomized, double-blind, clinical study showed an improvement in over-all/progression-free survival in patients with advanced melanomas. Ipilimumab is undergoing clinical trials for the treatment of melanoma, non-small cell lung cancer(NSCLC), small cell lung cancer(SCLC)and metastatic hormone-refractory prostate cancer, as well as other neoplastic diseases.